Opendata, web and dolomites

OvaVAx SIGNED

100% Bacteria free eggs for use in production of human and animal vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OvaVAx project word cloud

Explore the words cloud of the OvaVAx project. It provides you a very rough idea of what is the project "OvaVAx" about.

agr    cagr    team    germ    external    caulfield    utilising       coo    2021    gf    globally    manufacture    89bn    good    group    vision    benefits    demand    company    supplier    specialist    industries    immunisation    investors    global    biopharma    size    contamination    innovation    manufacturing    eliminate    yield    pandemic    manufacturers    pharmaceutical    invested    first    91m    leonard    providers    egg    entrepreneurs    service    founders    lives    led    fertilised    ovagen    vc    innovative    quality    populations    serial    disruptive    seven    health    ceo    2022    protect    protected    12    usd    patent    considerable    bacterial    moran    catherine    transgenics    ogl    free    ltd    expertise    industry    enterprise    exceptionally    pull    pathogen    services    ireland    avian       worth    superior    vaccine    biotechnology    chicken    annually    opportunity    whilst    eggs    vaccines    commercially    contract    viral    spf    servicing    standards    1bn    skills    dr    specialises    world    demands    48bn    rapid    market    yields   

Project "OvaVAx" data sheet

The following table provides information about the project.

Coordinator
OVAGEN GROUP LIMITED 

Organization address
address: CARRENTRILA
city: BALLINA
postcode: F26PC79
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙366˙875 €
 EC max contribution 2˙356˙812 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OVAGEN GROUP LIMITED IE (BALLINA) coordinator 2˙356˙812.00

Map

 Project objective

Disruptive technology for improved quality and viral yield in egg-based vaccine production and other biotechnology applications. Ovagen Group Ltd. (OGL) is an innovation-based biotechnology company, led by serial entrepreneurs, providing specialist contract services to Biopharma, Pharmaceutical and Vaccine industries. OGL specialises in avian Germ-Free (GF) technology and avian transgenics to Good Manufacturing Practice standards. The company’s vision is to be the go-to supplier of superior quality GF eggs to the vaccine industry globally by 2021.

INNOVATION: The founders Dr Leonard Moran CEO and Dr Catherine Caulfield COO together with external VC investors and Enterprise Ireland have invested €12.91M in seven years of R&D, utilising the considerable skills, expertise and experience of our team within this field to develop a unique and novel, patent protected process to enable commercially viable production of the World’s first germ-free (GF) eggs, to eliminate bacterial contamination through eggs for vaccine development and production. This will result in improved quality, production costs and viral yields for vaccine manufacturers leading to cost and availability benefits for health service providers for immunisation programmes to protect the health and lives of populations whilst enabling a rapid response to Global pandemic demands. There is exceptionally strong market pull for our innovative disruptive technology, and the increasing use of vaccines to support global demand for quality eggs estimated CAGR of 8.8% and market value of USD 1.89Bn by 2022.

OPPORTUNITY: Over 1bn fertilised specific pathogen free (SPF) chicken eggs are used annually in vaccine manufacture, servicing a vaccine market size estimated to be worth €48bn by 2021 with an AGR of 8.3%.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OVAVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OVAVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

TOM-E (2019)

TOM-E is the first GPS navigation device that is the less expensive on the market and multimodal. With Tom-E, riding has never been easier.

Read More